Agency Information Collection Activities: Proposed Collection; Comment Request, 7040-7042 [2018-03243]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
7040
Federal Register / Vol. 83, No. 33 / Friday, February 16, 2018 / Notices
Request for Comment
You can file a comment online or on
paper. For the FTC to consider your
comment, we must receive it on or
before March 19, 2018. Write ‘‘FPLA
Rules, PRA Comment, P074200’’ on
your comment. Your comment—
including your name and your state—
will be placed on the public record of
this proceeding, including, to the extent
practicable, on the public Commission
website, at https://www.ftc.gov/os/
publiccomments.shtm.
Postal mail addressed to the
Commission is subject to delay due to
heightened security screening. As a
result, we encourage you to submit your
comments online, or to send them to the
Commission by courier or overnight
service. To make sure that the
Commission considers your online
comment, you must file it at https://
ftcpublic.commentworks.com/ftc/
fplaregspra2, by following the
instructions on the web-based form.
When this Notice appears at https://
www.regulations.gov/#!home, you also
may file a comment through that
website.
If you file your comment on paper,
write ‘‘FPLA Rules, PRA Comment,
P074200’’ on your comment and on the
envelope, and mail it to the following
address: Federal Trade Commission,
Office of the Secretary, 600
Pennsylvania Avenue NW, Suite CC–
5610 (Annex J), Washington, DC 20580,
or deliver your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
Constitution Center, 400 7th Street SW,
5th Floor, Suite 5610 (Annex J),
Washington, DC 20024. If possible,
submit your paper comment to the
Commission by courier or overnight
service.
Because your comment will be placed
on the publicly accessible FTC website
at https://www.ftc.gov/, you are solely
responsible for making sure that your
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include any sensitive personal
information, such as your or anyone
else’s Social Security number; date of
birth; driver’s license number or other
state identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure that your
comment does not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
VerDate Sep<11>2014
19:24 Feb 15, 2018
Jkt 244001
commercial or financial information
which * * * is privileged or
confidential’’—as provided by Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—
including in particular competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
must be clearly labeled ‘‘Confidential,’’
and must comply with FTC Rule 4.9(c).
In particular, the written request for
confidential treatment that accompanies
the comment must include the factual
and legal basis for the request, and must
identify the specific portions of the
comment to be withheld from the public
record. See FTC Rule 4.9(c). Your
comment will be kept confidential only
if the General Counsel grants your
request in accordance with the law and
the public interest. Once your comment
has been posted on the public FTC
website—as legally required by FTC
Rule 4.9(b)—we cannot redact or
remove your comment from the FTC
website, unless you submit a
confidentiality request that meets the
requirements for such treatment under
FTC Rule 4.9(c), and the General
Counsel grants that request.
The FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before March 19, 2018. For information
on the Commission’s privacy policy,
including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/
site-information/privacy-policy. For
supporting documentation and other
information underlying the PRA
discussion in this Notice, see https://
www.reginfo.gov/public/jsp/PRA/
praDashboard.jsp.
Comments on the information
collection requirements subject to
review under the PRA should
additionally be submitted to OMB. If
sent by U.S. mail, they should be
addressed to Office of Information and
Regulatory Affairs, Office of
Management and Budget, Attention:
Desk Officer for the Federal Trade
Commission, New Executive Office
Building, Docket Library, Room 10102,
725 17th Street NW, Washington, DC
20503. Comments sent to OMB by U.S.
postal mail, however, are subject to
delays due to heightened security
precautions. Thus, comments instead
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
can also be sent by email to wliberante@
omb.eop.gov.
David C. Shonka,
Acting General Counsel.
[FR Doc. 2018–03289 Filed 2–15–18; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
Through this Request for
Information (RFI), the Agency for
Healthcare Research and Quality
(AHRQ) is seeking information from the
public, hospitals and other health care
organizations, clinicians, quality
improvement experts, researchers, and
quality measure developers about
current use of the AHRQ Quality
Indicators (AHRQ QIs) for quality
improvement efforts. AHRQ recognizes
that the AHRQ QIs have been adopted
for other uses, but for the purpose of
this RFI, the Agency is specifically
seeking information about quality
improvement initiatives such as those
that seek to: Improve clinical practice
(e.g., adherence to guidelines,
coordination of care); improve patient
safety or reduce harm; address
disparities in health or care; improve
prevention practices; and collaborate
with community groups to improve
health or care. AHRQ is also seeking
information about the ways in which
the Agency can increase use of the
AHRQ QI measures for quality
improvement, for example by refining
measures, summarizing best practices,
creating training materials, developing
standardized metrics, and/or convening
learning networks. To learn more about
the AHRQ QIs, visit https://
www.qualityindicators.ahrq.gov/.
DATES: Comments on this notice must be
received by the deadline on or before
March 8, 2018.
ADDRESSES: Written comments should
be submitted to: Maushami DeSoto,
Ph.D., MHA, Health Scientist
Administrator, Center for Delivery
Organization and Markets, Agency for
Healthcare Research and Quality, 5600
Fishers Lane, Rockville, MD 20857, or
by email at Maushami.Desoto@
ahrq.hhs.gov.
SUMMARY:
E:\FR\FM\16FEN1.SGM
16FEN1
Federal Register / Vol. 83, No. 33 / Friday, February 16, 2018 / Notices
FOR FURTHER INFORMATION CONTACT:
Maushami DeSoto, Ph.D. MHA, Health
Scientist Administrator, (301) 427–1546,
or by emails at Maushami.Desoto@
ahrq.hhs.gov.
The
mission of AHRQ is to produce
evidence to make health care safer;
higher quality; and more accessible,
equitable, and affordable. AHRQ works
within the U.S. Department of Health
and Human Services and with other
public and private partners to make sure
that the evidence is understood and
used. The Agency fulfills this mission
by supporting and conducting research;
generating needed evidence;
disseminating proven practices; creating
and distributing training materials for
health care systems and professionals;
and developing measures and data used
to track and improve performance. To
learn more about the Agency, visit
https://www.ahrq.gov/.
SUPPLEMENTARY INFORMATION:
daltland on DSKBBV9HB2PROD with NOTICES
Background
Over the years, use of the AHRQ QIs
has evolved. Originally developed to
support quality improvement at the
hospital and community levels, the
AHRQ QIs now serve several additional
purposes including: (1) Research; (2)
needs assessments for planning at the
local, state, and national levels; and (3)
performance assessment by private and
public value-based payment and
consumer choice programs. In the
current context, in which the purposes
and methods of measurement continue
to change rapidly, AHRQ is seeking
updated information to inform its own
planning and priority setting for future
work in the area of measures for quality
improvement. To do so, AHRQ must
define evidence criteria that are specific
to quality improvement and use those
criteria to determine which AHRQ QIs
work best for quality improvement and
how they can be improved for that
purpose.
As part of this effort, AHRQ is
conducting a literature review and
environmental scan to: (1) Document
knowledge and evidence on the
scientific acceptability of the AHRQ QIs
for quality improvement; (2) document
and synthesize information about the
strengths and limitations of the AHRQ
QIs; (3) identify areas of disagreement,
if any, in the evidence; and (4) develop
suggestions for refinement or
improvement in the indicators,
particularly those that make the AHRQ
QIs more useful for quality
improvement. As part of the
environmental scan, AHRQ is issuing
this RFI to obtain information from
stakeholders who have not published
VerDate Sep<11>2014
19:24 Feb 15, 2018
Jkt 244001
their experiences using the AHRQ QIs
or who wish to provide additional
information beyond what they have
published. AHRQ will review results
from the literature review and
environmental scan and release a
summary report in December 2018.
Specific questions of interest to the
Agency include, but are not limited to:
For Hospitals or Other Health Care
Entities That CURRENTLY USE
AHRQ QIs for Quality Improvement:
1. What type of organization do you
represent?
2. How does your organization define
quality improvement?
3. How does your organization use the
AHRQ QIs for quality improvement? For
example, do you use them for
identifying patient safety problems,
identifying quality improvement
opportunities, and/or tracking
performance over time?
4. Which specific AHRQ QIs does
your organization use for quality
improvement? Please include the
number of each QI, for example, PQI 05,
which can be found at the AHRQ QI
website.
5. Have you stopped using an AHRQ
QI for quality improvement? If yes,
please identify it and explain why you
stopped.
6. Of the AHRQ QIs you use now or
used previously, which ones have been
most valuable in improving quality?
a. What are the strengths of each
measure you have used?
b. What are the weaknesses of each
measure you have used?
7. What other methodological and/or
data quality issues have you
encountered when using AHRQ QIs for
quality improvement that you haven’t
already mentioned?
8. Does your organization use
measures other than the AHRQ QIs for
quality improvement? If yes, which ones
and what types of quality improvement
initiatives does your organization use
them for? How do they compare to the
AHRQ QIs in terms of ease of use and
impact on quality?
9. What changes and refinements to
the AHRQ QIs would make them easier
to use for quality improvement?
10. What changes and refinements to
the AHRQ QIs would make them more
effective for improving quality?
11. What resources would aid the
uptake of the AHRQ QIs for quality
improvement?
12. What improvements are needed to
current AHRQ QI resources? These
include resources available through the
QI website such as tool kits, case
studies, webinars, presentations,
publication lists, video tutorials (WinQI
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
7041
and SASQI), measure technical
specifications (IQI, PQI, PSI, PDI), TA
support, FAQs, and software.
13. If you operate a community health
center, which AHRQ QIs do you use for
quality improvement in the community
health center? Which other measures do
you use for quality improvement in the
community health center?
14. If you operate a hospital
emergency department (ED), which
AHRQ QIs do you use for quality
improvement in the ED? Which other
measures do you use for quality
improvement in the ED?
For Hospitals or Other Health Care
Entities That Are NOT CURRENTLY
USING Any AHRQ QIs for Quality
Improvement:
15. How does your organization
define quality improvement?
16. What types of quality
improvement initiatives does your
organization engage in?
17. Have you heard of the AHRQ QIs?
If yes, what do you know about them?
18. What factors contribute to your
organization’s decision to not use the
AHRQ QIs?
19. Has your organization used the
AHRQ QIs in the past? If so, why is your
organization no longer using them?
20. What measures does your
organization use for quality
improvement? What are some of the
reasons/factors your organization uses
these measures?
21. If you operate a community health
center, which measures do you use for
quality improvement?
22. If you operate a hospital
emergency department (ED), which
measures do you use for quality
improvement?
23. If your organization is a
community health center, which metrics
do you use for quality improvement?
24. If your organization is an ED
which metrics do you use for quality
improvement and monitoring?
AHRQ is interested in all the
questions listed above, but respondents
are welcome to address as many or as
few as they choose and to address
additional areas of interest not listed.
AHRQ will use the information it
receives to assist in developing future
initiatives. These initiatives may
include, but are not limited to,
developing research grant and
contracting opportunities, investing in
the creation of tools and training
materials for health professionals and
health care delivery organizations,
developing quality improvement
measures, and/or convening learning
collaboratives.
E:\FR\FM\16FEN1.SGM
16FEN1
7042
Federal Register / Vol. 83, No. 33 / Friday, February 16, 2018 / Notices
Health care professionals and
organizations are encouraged to respond
to this RFI by submitting a written
statement and supporting explanatory
materials to the email or mailing
address listed above by February 28,
2018. Supporting materials might
include charters for quality and safety
improvement committees, data use
agreements for learning collaboratives,
population health metrics and reports,
or guidelines for the use of evidencebased practices. When responding to
questions listed above, please clearly
indicate the number of the question that
is being addressed. AHRQ encourages
respondents to include a description of
their health care delivery organization at
the beginning of their response to
provide context for the information they
provide.
Request for Comments
This RFI is for planning purposes
only and should not be construed as a
policy, solicitation for applications, or
as an obligation on the part of the
Government to provide support for any
ideas identified in response to it. AHRQ
will use the information submitted in
response to this RFI at its discretion and
will not provide comments to any
responder’s submission. However,
responses to the RFI may be reflected in
future solicitation(s) or policies. The
information provided will be analyzed
and may appear in reports. Respondents
will not be identified in any published
reports. Respondents are advised that
the Government is under no obligation
to acknowledge receipt of the
information received or provide
feedback to respondents with respect to
any information submitted. No
proprietary, classified, confidential, or
sensitive information should be
included in your response. The
Government reserves the right to use
any non-proprietary technical
information in any resultant
solicitation(s). The contents of all
submissions will be made available to
the public upon request. Materials
submitted must be publicly available or
can be made public.
daltland on DSKBBV9HB2PROD with NOTICES
Gopal Khanna,
Director.
[FR Doc. 2018–03243 Filed 2–15–18; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2015–E–3856; FDA–
2015–E–3857]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; MOVANTIK
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for MOVANTIK and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of applications to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
SUMMARY:
Anyone with knowledge that any
of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by April 17, 2018. See
‘‘Petitions’’ in the SUPPLEMENTARY
INFORMATION section for more
information.
DATES:
You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before April 17,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of April 17, 2018. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date. Furthermore, any interested
person may petition FDA for a
determination regarding whether the
applicant for extension acted with due
diligence during the regulatory review
period by August 15, 2018. See
‘‘Petitions’’ in the SUPPLEMENTARY
INFORMATION section for more
information.
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
VerDate Sep<11>2014
19:24 Feb 15, 2018
Jkt 244001
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket Nos. FDA
2015–E–3856 and FDA 2015–E–3857 for
‘‘Determination of Regulatory Review
Period for Purposes of Patent Extension;
MOVANTIK.’’ Received comments,
those filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 83, Number 33 (Friday, February 16, 2018)]
[Notices]
[Pages 7040-7042]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-03243]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Agency for Healthcare Research and Quality, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Through this Request for Information (RFI), the Agency for
Healthcare Research and Quality (AHRQ) is seeking information from the
public, hospitals and other health care organizations, clinicians,
quality improvement experts, researchers, and quality measure
developers about current use of the AHRQ Quality Indicators (AHRQ QIs)
for quality improvement efforts. AHRQ recognizes that the AHRQ QIs have
been adopted for other uses, but for the purpose of this RFI, the
Agency is specifically seeking information about quality improvement
initiatives such as those that seek to: Improve clinical practice
(e.g., adherence to guidelines, coordination of care); improve patient
safety or reduce harm; address disparities in health or care; improve
prevention practices; and collaborate with community groups to improve
health or care. AHRQ is also seeking information about the ways in
which the Agency can increase use of the AHRQ QI measures for quality
improvement, for example by refining measures, summarizing best
practices, creating training materials, developing standardized
metrics, and/or convening learning networks. To learn more about the
AHRQ QIs, visit https://www.qualityindicators.ahrq.gov/.
DATES: Comments on this notice must be received by the deadline on or
before March 8, 2018.
ADDRESSES: Written comments should be submitted to: Maushami DeSoto,
Ph.D., MHA, Health Scientist Administrator, Center for Delivery
Organization and Markets, Agency for Healthcare Research and Quality,
5600 Fishers Lane, Rockville, MD 20857, or by email at
[email protected].
[[Page 7041]]
FOR FURTHER INFORMATION CONTACT: Maushami DeSoto, Ph.D. MHA, Health
Scientist Administrator, (301) 427-1546, or by emails at
[email protected].
SUPPLEMENTARY INFORMATION: The mission of AHRQ is to produce evidence
to make health care safer; higher quality; and more accessible,
equitable, and affordable. AHRQ works within the U.S. Department of
Health and Human Services and with other public and private partners to
make sure that the evidence is understood and used. The Agency fulfills
this mission by supporting and conducting research; generating needed
evidence; disseminating proven practices; creating and distributing
training materials for health care systems and professionals; and
developing measures and data used to track and improve performance. To
learn more about the Agency, visit https://www.ahrq.gov/.
Background
Over the years, use of the AHRQ QIs has evolved. Originally
developed to support quality improvement at the hospital and community
levels, the AHRQ QIs now serve several additional purposes including:
(1) Research; (2) needs assessments for planning at the local, state,
and national levels; and (3) performance assessment by private and
public value-based payment and consumer choice programs. In the current
context, in which the purposes and methods of measurement continue to
change rapidly, AHRQ is seeking updated information to inform its own
planning and priority setting for future work in the area of measures
for quality improvement. To do so, AHRQ must define evidence criteria
that are specific to quality improvement and use those criteria to
determine which AHRQ QIs work best for quality improvement and how they
can be improved for that purpose.
As part of this effort, AHRQ is conducting a literature review and
environmental scan to: (1) Document knowledge and evidence on the
scientific acceptability of the AHRQ QIs for quality improvement; (2)
document and synthesize information about the strengths and limitations
of the AHRQ QIs; (3) identify areas of disagreement, if any, in the
evidence; and (4) develop suggestions for refinement or improvement in
the indicators, particularly those that make the AHRQ QIs more useful
for quality improvement. As part of the environmental scan, AHRQ is
issuing this RFI to obtain information from stakeholders who have not
published their experiences using the AHRQ QIs or who wish to provide
additional information beyond what they have published. AHRQ will
review results from the literature review and environmental scan and
release a summary report in December 2018.
Specific questions of interest to the Agency include, but are not
limited to:
For Hospitals or Other Health Care Entities That CURRENTLY USE AHRQ QIs
for Quality Improvement:
1. What type of organization do you represent?
2. How does your organization define quality improvement?
3. How does your organization use the AHRQ QIs for quality
improvement? For example, do you use them for identifying patient
safety problems, identifying quality improvement opportunities, and/or
tracking performance over time?
4. Which specific AHRQ QIs does your organization use for quality
improvement? Please include the number of each QI, for example, PQI 05,
which can be found at the AHRQ QI website.
5. Have you stopped using an AHRQ QI for quality improvement? If
yes, please identify it and explain why you stopped.
6. Of the AHRQ QIs you use now or used previously, which ones have
been most valuable in improving quality?
a. What are the strengths of each measure you have used?
b. What are the weaknesses of each measure you have used?
7. What other methodological and/or data quality issues have you
encountered when using AHRQ QIs for quality improvement that you
haven't already mentioned?
8. Does your organization use measures other than the AHRQ QIs for
quality improvement? If yes, which ones and what types of quality
improvement initiatives does your organization use them for? How do
they compare to the AHRQ QIs in terms of ease of use and impact on
quality?
9. What changes and refinements to the AHRQ QIs would make them
easier to use for quality improvement?
10. What changes and refinements to the AHRQ QIs would make them
more effective for improving quality?
11. What resources would aid the uptake of the AHRQ QIs for quality
improvement?
12. What improvements are needed to current AHRQ QI resources?
These include resources available through the QI website such as tool
kits, case studies, webinars, presentations, publication lists, video
tutorials (WinQI and SASQI), measure technical specifications (IQI,
PQI, PSI, PDI), TA support, FAQs, and software.
13. If you operate a community health center, which AHRQ QIs do you
use for quality improvement in the community health center? Which other
measures do you use for quality improvement in the community health
center?
14. If you operate a hospital emergency department (ED), which AHRQ
QIs do you use for quality improvement in the ED? Which other measures
do you use for quality improvement in the ED?
For Hospitals or Other Health Care Entities That Are NOT CURRENTLY
USING Any AHRQ QIs for Quality Improvement:
15. How does your organization define quality improvement?
16. What types of quality improvement initiatives does your
organization engage in?
17. Have you heard of the AHRQ QIs? If yes, what do you know about
them?
18. What factors contribute to your organization's decision to not
use the AHRQ QIs?
19. Has your organization used the AHRQ QIs in the past? If so, why
is your organization no longer using them?
20. What measures does your organization use for quality
improvement? What are some of the reasons/factors your organization
uses these measures?
21. If you operate a community health center, which measures do you
use for quality improvement?
22. If you operate a hospital emergency department (ED), which
measures do you use for quality improvement?
23. If your organization is a community health center, which
metrics do you use for quality improvement?
24. If your organization is an ED which metrics do you use for
quality improvement and monitoring?
AHRQ is interested in all the questions listed above, but
respondents are welcome to address as many or as few as they choose and
to address additional areas of interest not listed. AHRQ will use the
information it receives to assist in developing future initiatives.
These initiatives may include, but are not limited to, developing
research grant and contracting opportunities, investing in the creation
of tools and training materials for health professionals and health
care delivery organizations, developing quality improvement measures,
and/or convening learning collaboratives.
[[Page 7042]]
Health care professionals and organizations are encouraged to
respond to this RFI by submitting a written statement and supporting
explanatory materials to the email or mailing address listed above by
February 28, 2018. Supporting materials might include charters for
quality and safety improvement committees, data use agreements for
learning collaboratives, population health metrics and reports, or
guidelines for the use of evidence-based practices. When responding to
questions listed above, please clearly indicate the number of the
question that is being addressed. AHRQ encourages respondents to
include a description of their health care delivery organization at the
beginning of their response to provide context for the information they
provide.
Request for Comments
This RFI is for planning purposes only and should not be construed
as a policy, solicitation for applications, or as an obligation on the
part of the Government to provide support for any ideas identified in
response to it. AHRQ will use the information submitted in response to
this RFI at its discretion and will not provide comments to any
responder's submission. However, responses to the RFI may be reflected
in future solicitation(s) or policies. The information provided will be
analyzed and may appear in reports. Respondents will not be identified
in any published reports. Respondents are advised that the Government
is under no obligation to acknowledge receipt of the information
received or provide feedback to respondents with respect to any
information submitted. No proprietary, classified, confidential, or
sensitive information should be included in your response. The
Government reserves the right to use any non-proprietary technical
information in any resultant solicitation(s). The contents of all
submissions will be made available to the public upon request.
Materials submitted must be publicly available or can be made public.
Gopal Khanna,
Director.
[FR Doc. 2018-03243 Filed 2-15-18; 8:45 am]
BILLING CODE 4160-90-P
